Transfusion-associated graft versus host disease overview
|
Transfusion-associated graft versus host disease Microchapters |
|
Differentiating Transfusion-associated graft versus host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Transfusion-associated graft versus host disease overview On the Web |
|
American Roentgen Ray Society Images of Transfusion-associated graft versus host disease overview |
|
FDA on Transfusion-associated graft versus host disease overview |
|
CDC on Transfusion-associated graft versus host disease overview |
|
Transfusion-associated graft versus host disease overview in the news |
|
Blogs on Transfusion-associated graft versus host disease overview |
|
Directions to Hospitals Treating Transfusion-associated graft versus host disease |
|
Risk calculators and risk factors for Transfusion-associated graft versus host disease overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Transfusion-associated graft versus host disease (TA-GvHD) is a rare complication of blood transfusion, in which the donor T lymphocytes mount an immune response against the recipient's lymphoid tissue. Donor lymphocytes are usually identified as foreign and destroyed by the recipient's immune system. However, in situations where the recipient is immunocompromised (inborn immunodeficiency, acquired immunodeficiency, malignancy), or when the donor is homozygous and the recipient is heterozygous for an HLA haplotype (as can occur in directed donations from first-degree relatives), the recipient's immune system is not able to destroy the donor lymphocytes. This can result in graft versus host disease.